EP4403230A3 — Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals

USPTO Abstract

The present invention relates to combination of one or more SGLT2 inhibitors or pharmaceutically acceptable forms and/or salts thereof and one or more dopamine receptor agonists or pharmaceutically acceptable forms and/or salts thereof, preferably in the treatment and/or prevention of a metabolic disorder of an equine animal, wherein more preferably the metabolic disorder is one or more disorders selected from Equine Metabolic Syndrome (EMS), Equine Pituitary Pars Intermedia Dysfunction (PPID), also known as equine Cushing's syndrome, laminitis, vascular dysfunction, hypertension, hepatic lipidosis, hyperadrenocorticism, glucose intolerance, insulin resistance, hyperinsulinaemia, hirsutism, hyperhidrosis, polyuria, polydipsia, chronic infections, abnormal fat distribution, muscle wasting, abnormal weight loss and/or loss of appetite.